Jeff Yass’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-3,675
| Closed | -$47K | – | 13643 |
|
|
2022
Q4 | $47K | Sell |
3,675
-875
| -19% | -$13K | ﹤0.01% | 11430 |
|
|
2022
Q3 | $71K | Buy |
4,550
+3,894
| +594% | +$74.6K | ﹤0.01% | 11984 |
|
|
2022
Q2 | $13K | Buy |
656
+69
| +12% | +$1.73K | ﹤0.01% | 12464 |
|
|
2022
Q1 | $22K | Buy |
587
+429
| +272% | +$15.4K | ﹤0.01% | 12601 |
|
|
2021
Q4 | $6K | Sell |
158
-873
| -85% | -$46K | ﹤0.01% | 12977 |
|
|
2021
Q3 | $77K | Sell |
1,031
-3,712
| -78% | -$264K | ﹤0.01% | 12191 |
|
|
2021
Q2 | $416K | Sell |
4,743
-2,101
| -31% | -$200K | ﹤0.01% | 10032 |
|
|
2021
Q1 | $780K | Buy |
+6,844
| New | +$759K | ﹤0.01% | 8373 |
|
|
2020
Q2 | – | Sell |
-100
| Closed | -$5K | – | 11084 |
|
|
2020
Q1 | $5K | Hold |
100
| – | – | ﹤0.01% | 10109 |
|
|
2019
Q4 | $9K | Sell |
100
-167
| -63% | -$15.6K | ﹤0.01% | 9557 |
|
|
2019
Q3 | $28K | Buy |
267
+79
| +42% | +$17.1K | ﹤0.01% | 9905 |
|
|
2019
Q2 | $55K | Buy |
+188
| New | +$66.3K | ﹤0.01% | 9823 |
|
|
2019
Q1 | – | Sell |
-137
| Closed | -$40K | – | 9999 |
|
|
2018
Q4 | $40K | Buy |
+137
| New | +$32.7K | ﹤0.01% | 8550 |
|
|
2017
Q2 | – | Sell |
-159
| Closed | -$48K | – | 9945 |
|
|
2017
Q1 | $48K | Buy |
+159
| New | +$46.8K | ﹤0.01% | 8603 |
|
Other funds holding CSCI
Jeff Yass's CSCI Position: Q3 2025 in Review
Jeff Yass sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2025, closing a stake of 11,504 shares — an estimated $39K sold.
Jeff Yass first reported a position in CSCI in Q1 2014 and held it in 24 quarters. The position peaked at $4.58M in Q1 2015. 2 funds tracked by Wall St. Rank hold CSCI as of Q3 2025.
- Jeff Yass reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
- Jeff Yass sold 11,504 COSCIENS Biopharma Inc. Common Stock shares in Q3 2025, an estimated $39K.
- Jeff Yass first reported a position in COSCIENS Biopharma Inc. Common Stock in Q1 2014 and held it in 24 quarters.
- Jeff Yass's COSCIENS Biopharma Inc. Common Stock position peaked at $4.58M in Q1 2015.
- 2 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.